Use the Hepatitis A case investigation form; download a current
copy from the Internet.
Transmission is almost entirely fecal-oral, and may occur through fecal
contamination of food by poor food handling practices; fecal contamination
and inadequate treatment of drinking water; and ingestion of fecal material
transferred by direct personal contact, including ual contact.
The concentration of virus in stool (and therefore infectivity) varies
over the course of infection; it is highest before onset of symptoms.
Roughly 7--8% of the working population work as food handlers, and about
the same proportion show up as hepatitis A cases.
Both food service facility operators and public health authorities should
recognize their responsibility to protect the public's health.
hepatitis
The disease can vary from mild to severe.
About 50% of people with hepatitis have no symptoms and may not know they
have it.
The virus causing type A hepatitis, also known as infectious hepatitis,
leaves the body in the feces, or bowel wastes.
Type A hepatitis is most commonly seen among children in day care centers,
school age children and young adults.
A baby can get hepatitis B at birth from the mother or be infected before
birth.
If your child has been playing with another child who gets hepatitis,
you should talk to your child's doctor.
This will prevent the hepatitis B infection and keep your child from becoming
a long-term carrier of the virus.
0000067
In this policy, the expression "students with HIV or HBV"
is used to describe students who are (as the case may be) HIV positive,
Hepatitis B e-antigen positive or Hepatitis B DNA positive.
The University will not discriminate unlawfully against students with
HIV or HBV.
Students with HIV or HBV in the Faculties of Medicine, Nursing and Health
Sciences Although the clinical work undertaken by students in a number
of academic programs at the Faculty of Medicine would normally include
"exposure-prone procedures" as defined by the NSW Health Department,
students with HIV or HBV who refrain from performing any of these procedures
will not be prevented from graduating for this reason.
12002022
1. PURPOSE: This Veterans Health Administration (VHA) Directive
defines policies on the need for implementation of a national Hepatitis
C Case Registry system within the Veterans Health Information Systems
Technology Architecture (VistA) software.
The number of veterans with Hepatitis C infection is believed to be large,
the data systems currently available, however, are insufficient to accurately
measure the extent of the problem or to ensure that services and resources
are adequately budgeted and distributed in response.
3. POLICY: It is VHA policy that Veterans Integrated Service Network (VISN)
and facility Directors must provide a national Hepatitis C Case Registry
by ensuring the installation, set-up, and maintenance of each facility's
VistA registry software (which is ROR_V1).
HepatitisBandHaemophilusImmunizationsProgs
http://www.ihs.gov These figures represent patients immunized in hepatitis A/B
studies, and adult vaccination with program-purchased vaccine.
Changes in figures represent hepatitis A vaccination of adults with chronic
hepatitis C infection.
The Hepatitis B Program began in 1982 to stop the spread of hepatitis
B in Alaska Natives by mass immunization, and to prevent premature death
in chronically infected persons by early liver cancer detection.
Total Request -- The request of $1,526,000 is an increase of $55,000 over
the FY 2001 enacted level of $1,471,000.
Maintaining the current I/T/U health system to ensure access and continuity
of care is necessary in eliminating disparities in health status between
AI/ANs and the rest of the U.S. population.
HEP A_faq
If the hepatitis A virus exists in the stool of infected people
and is most commonly transmitted through contact with stool, why should
people who are careful to be clean worry about it?
1 Hepatitis A infection rates are higher in some geographic areas than
in others, although the reasons for these differences are not fully understood.
Some groups of people are at increased risk of infection and should be
protected by the vaccine including international travelers, men who have
with men, injecting drug users, laboratory workers who may come in
contact with the virus, and people with hemophilia or clotting-factor
disorders who receive blood products.
perin
http://www.health.state.ny.us/nysdoh/epi/93/perin.pdf New York State has a unique program for perinatal hepatitis
B virus (HBV) surveillance and control.
A public health law which became effective May 10, 1990, mandates universal
testing of all pregnant women and reporting and treatment of all infants
born to hepatitis B surface antigen (HBsAg) positive mothers.
The treatment of infants born to HBsAg positive women with hepatitis B
immune globulin (HBIG) and hepatitis B vaccine is 85-95 percent effective
in preventing chronic hepatitis B infection; vaccine alone is 70-80 percent
effective.
If vaccine is not immediately available, the first dose can be given within
the first seven days after birth.
seh-10
Hepatitis B is a serious disease caused by the hepatitis B
virus (HBV), which is present in the blood and body fluids of an infected
individual.
HBV infection can cause acute illness that leads to loss of appetite,
tiredness, pain in muscles, joints, or stomach, diarrhea or vomiting,
and yellow skin or eyes (jaundice).
HBV can also cause chronic infection, especially in infants and children,
which leads to liver damage (cirrhosis), liver cancer, and death.
Transmission could occur in the school setting as a result of exposure
to infected blood.
The hepatitis B vaccination is a noninfectious vaccine given in three
injections in the upper arm.
091091
http://www.fda.gov/cber/bldmem/091091.pdf After 31 March 1991 anti-HBc kits shipped in interstate commerce
and labeled for use in screening blood and blood products must bear a
U.S. license number.
FDA is not recommending the exclusion of repeatedly reactive anti-HBc
plasma from pools for further manufacture into plasma derivatives because
the exclusion of such products might result in decreased safety of plasma
derivatives by a likely reduction of antibody to hepatitis B surface antigen
(anti-HBs).
For this reason, testing of Source Plasma for further manufacturing is
not recommended at this time, Although recovered plasma is harvested from
donations that have been tested for anti-HBc, it may be shipped for further
manufacturing under a valid short supply agreement regardless of the test
results.
vol18n5
http://www.dph.state.ct.us/Publications/BCH/Infectious
Diseases/vol18n5.pdf encourages all clinical care providers to be aware of interventions
designed to reduce transmission of hepatitis A, B, and C.
The most important methods for preventing transmission involve adequate
sanitation and personal hygiene (particularly among food handlers and
persons who provide care to young children), and vaccination with a HAV
vaccine.
Two vaccines are available in the United States and have been shown to
be highly effective in providing lasting protection against HAV infection.
Providers can minimize the potential for HAV spread by vaccinating all
eligible persons against HAV prior to exposure, by appropriately managing
household contacts of persons with hepatitis A, and by both confirming
the diagnosis and reporting suspect cases to the local and state health
departments.
hepatitis a
Dear Parent/Guardian: There is a child in your child's class
who has been diagnosed with Hepatitis A. HEPATITIS A
In recent years, childcare settings have been recognized as an important
source of hepatitis A epidemics, with spread into the community.
Provider: This disease is reportable to the local or state health department.
1. Wash hands thoroughly with soap and warm running water after using
the toilet, changing diapers, and before preparing or eating food.
Add 1/4 cup bleach to 1 gallon of water or to make a smaller amount in
a spray bottle add 1 tablespoon bleach to 1quart of water.
WHO_hep_B_update
· So far, more than 80 countries have integrated hepatitis
B (HB) vaccine into their EPI, up from 20 countries in 1990.
Carriage of hepatitis B virus (HBV) has already been reduced from high
prevalence to low prevalence in immunized cohorts of children in many
countries.
Three quarters of the world's population live in areas where there are
high levels of infection.
About 25% of carriers (1 million a year) will die from chronic active
hepatitis, cirrhosis or primary liver cancer.
· In 1992, the World Health Assembly confirmed the target of introducing
HB vaccine into national immunization programmes in all countries by 1997.
brochure
http://www.masshepc.org/pdfs/brochure.PDF here is no vaccine for hepatitis C, but you can take steps
to protect yourself: Avoid any direct contact with blood.
You should talk to your health care provider about ways to protect your
health.
Check with a health care provider before taking any medications (prescription
or nonprescription).
Learn how to avoid spreading the virus to others.
For example, don't share razors, toothbrushes or any other items that
might contain blood.
Hepatitis C is a virus that causes liver disease.
This can happen if you share needles to inject drugs, for example.
At its worst, hepatitis C can cause liver failure and even death.
safety
This document is meant as a short introduction to the literature
concerning potential adverse events following hepatitis B vaccination
and their impact, the subject of the Viral Hepatitis Prevention Board
(VHPB) meeting in Geneva, March 13-14, 2003.
The following subjects will be treated and discussed in separate sessions:
Adverse events following hepatitis B vaccination: multiple sclerosis;
effects of thiomersal; effects of aluminium; leukaemia; and autoimmune
diseases.
Communication: the Global Advisory Committee on Vaccine Safety (GACVS)
and its communication strategy; the role of the industry; considerations
on The Brighton Collaboration; countering the anti-vaccination movement
and vaccination 'scares'; and working with the media.
Ball LK, Evans G, Bostrom A. Risky business: challenges in vaccine risk
communication.
The Brighton Collaboration: addressing the need for standardized case
definitions of adverse events following immunization (AEFI).
